Accessibility Menu
Camurus Ab (publ) logo

Camurus Ab (publ)(OTC) CAMRF

Market Cap$3.48BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)+279%
5 Year+354%
1 Year-18%
1 Month-4%
$64.00
+0.00%
+0.00Today
Camurus Ab (publ) last closing stock price
MetricPriceDate
Last closeUSD 58.512026-07-31
Camurus Ab (publ) stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 58.512026-07-17
1 month-4.1%USD 61.012026-06-30
3 month-7.57%USD 63.302026-04-20
Year to date-12.83%USD 67.132025-12-31
1 year-17.59%USD 71.002025-07-31
3 year+168.27%USD 21.812023-05-22
5 year+353.57%USD 12.902021-06-30
Since inception+279.34%USD 15.422017-12-11

Camurus Ab (publ) Financials at a Glance

Market Cap

$3.48BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

SEK 2.26B

Net Income (TTM)

SEK 676.36M

EPS (TTM)

$1.21

P/E Ratio

48.15

Dividend

$0.00

Beta (Volatility)

0.07 (Low)

Price

$64.00

Volume

1,500

Open

$64.00

Previous Close

$58.51

Daily Range

$64.00 - $64.00

52-Week Range

$54.00 - $71.00

Estimated Earnings Date

Nov 5, 2026

CAMRF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Camurus Ab (publ)

Camurus AB is a research-based pharmaceutical company focused on developing and commercializing specialty medicines. The company addresses severe and chronic conditions, including opioid dependence, pain, cancer, and endocrine disorders. Founded in 1991 and headquartered in Lund, Sweden, Camurus is committed to innovative healthcare solutions.

Products and Services
  • Specialty medicines for opioid dependence
  • Innovative treatments for chronic pain management
  • Therapies for cancer and endocrine disorders
Growth Outlook
  • Recent quarterly revenue reached SEK 702 million, a significant increase
  • Net income for Q2 2026 was SEK 240 million, showcasing profitability
  • Strong cash position with SEK 4.07 billion in cash and equivalents
Financial Highlights
  • Trailing twelve months (TTM) revenue of SEK 2.4 billion, reflecting robust growth
  • Operating profit margin of 41.7%, indicating operational efficiency
  • Net profit margin of 29.9%, demonstrating strong profitability
Camurus AB operates in the healthcare sector, specifically within the pharmaceutical industry, and has shown impressive financial performance in recent quarters. The company’s focus on specialty medicines positions it well in a growing market, particularly as the demand for innovative treatments continues to rise. The recent quarterly results highlight a strong revenue growth trajectory, with a notable increase in net income, reflecting effective cost management and operational efficiency. The company's solid cash position provides a strong foundation for future investments in research and development, which is crucial for sustaining growth and expanding its product portfolio. With a commitment to addressing significant health challenges, Camurus AB is well-positioned to capitalize on emerging opportunities in the pharmaceutical landscape.
AI Generated • Aug 1, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

301

CEO

Sven Fredrik Tiberg, PhD

Website

www.camurus.com

Headquarters

Lund, SN 223 70, SE

CAMRF Financials

Key Financial Metrics (TTM)

Gross Margin

92.49%

Operating Margin

36.33%

Net Income Margin

29.92%

Return on Equity

15.54%

Return on Capital

20.13%

Return on Assets

12.78%

Earnings Yield

2.08%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.48BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

59.51M

Volume

1.50K

Avg. Volume

110.746

Financials (TTM)

Gross Profit

SEK 2.09B

Operating Income

SEK 821.15M

EBITDA

SEK 891.79M

Operating Cash Flow

SEK 810.89M

Capital Expenditure

-SEK 156.50M

Free Cash Flow

SEK 654.06M

Cash & ST Invst.

SEK 4.07B

Total Debt

SEK 108.40M

Camurus Ab (publ) Performance Analysis

Camurus Ab (publ) annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31SEK 94,500,99535.1%
20232023-12-31SEK 161,723,72571.1%
20242024-12-31SEK 176,641,3079.2%
20252025-12-31SEK 230,984,03730.8%
Camurus Ab (publ) sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-16.6%
Q42025-12-31-17.5%
Q12026-03-3114.4%
Q22026-06-3032.1%
Camurus Ab (publ) annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31SEK 0.10N/A
20232023-12-31SEK 0.71608.9%
20242024-12-31SEK 0.68-3.7%
20252025-12-31SEK 1.2583.5%
Camurus Ab (publ) sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-21.8%
Q42025-12-31-47.6%
Q12026-03-3143.7%
Q22026-06-3068.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

SEK 702.08M

+3.9%

Gross Profit

SEK 657.94M

+3.7%

Gross Margin

93.71%

N/A

Market Cap

$3.48BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$12.22M

N/A

Employees

285

N/A

Net Income

SEK 240.83M

-1.6%

EBITDA

SEK 318.23M

+1.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

SEK 4.07B

+21.5%

Total Debt

SEK 108.40M

+2.4%

Accounts Receivable

SEK 708.66M

+0.4%

Inventory

SEK 149.68M

+20.9%

Long Term Debt

SEK 86.82M

+2.6%

Short Term Debt

SEK 21.58M

+1.7%

Return on Assets

12.78%

N/A

Return on Invested Capital

17.10%

N/A

Free Cash Flow

SEK 193.13M

-44.8%

Operating Cash Flow

SEK 234.49M

-37.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TLPPFTelix Pharmaceuticals Limited
$11.50-2.74%
AMBBYAmbu A/S
$10.86+0.00%
SNPHFSanten Pharmaceutical Co., Ltd.
$13.05+0.00%
GLPGFGalapagos N.V.
$26.24+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.13+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.61-0.00%
ONDSOndas
$9.15+0.03%
SPCXSpace Exploration Technologies
$139.59-0.01%

Questions About CAMRF

What is the current price of Camurus Ab (publ)?

Camurus Ab (publ) is trading at $64.00 per share.

What is the 52-week range for Camurus Ab (publ)?

Over the past 52 weeks, Camurus Ab (publ) has traded between $54.00 and $71.00.

How much debt does Camurus Ab (publ) have?

As of the most recent reporting period, Camurus Ab (publ) reported total debt of SEK 11.20M.

How much cash does Camurus Ab (publ) have on hand?

Camurus Ab (publ) reported SEK 420.39M in cash and cash equivalents in its most recent financial results.

What is Camurus Ab (publ)’s dividend yield?

Camurus Ab (publ) does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services